The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Adiponectin and its receptors in non-alcoholic steatohepatitis
Open accessAbstract
Background: Adiponectin, an adipocyte derived polypeptide, has been shown to alleviate steatosis and inflammation in mice with non-alcoholic fatty liver disease. Aim: In the present study, we wished to define liver expression of adiponectin and its receptors in morbidly obese patients undergoing bariatric surgery. Patients with non-alcoholic steatohepatitis (NASH) or simple steatosis were investigated to test whether dysregulation of this system might be involved in these disorders. Patients and methods: Liver mRNA expression of adiponectin and its recently cloned receptors RI and RII (adipoRI and adipoRII) were analysed by fluorescence based real time polymerase chain reaction in 13 patients with NASH and nine with simple steatosis. Adiponectin and adipoRII protein expression were assessed by immunohistochemistry in a subgroup of patients. Results: Adiponectin and adipoRII mRNA expression were significantly reduced in liver biopsies of patients with NASH compared with simple steatosis while no difference was found in adipoRI mRNA expression. In NASH, adipoRII mRNA expression was negatively correlated with serum aspartate aminotransferase levels, serum alanine aminotransferase levels, and grade of fibrosis. Liver adiponectin protein expression was mainly found in endothelial cells of portal vessels and liver sinusoids whereas adipoRII expression was seen in hepatocytes only. Adiponectin and adipoRII staining were lower in biopsies of subjects with NASH compared with simple steatosis. Conclusion: Reduced hepatic expression of adiponectin and adipoRII might be of pathophysiological relevance in non-alcoholic fatty liver diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M., Hara, K., Tsunoda, M., et al. (2003) · Nature · doi:10.1038/nature01705 · Cited by 3,176
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. (2001) · Nature Medicine · doi:10.1038/90992 · Cited by 2,526
Fruebis, J., Tsao, T., Javorschi, S., Ebbets-Reed, D., Erickson, M., Yen, F. T., Bihain, B. E., & Lodish, H. F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041591798 · Cited by 1,985
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Yokota, T., Oritani, K., Takahashi, I., Ishikawa, J., Matsuyama, A., Ouchi, N., Kihara, S., Funahashi, T., Tenner, A. J., Tomiyama, Y., et al. (2000) · Blood · doi:10.1182/blood.v96.5.1723 · Cited by 1,297
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,296
Ouchi, N., Kihara, S., Arita, Y., Nishida, M., Matsuyama, A., Okamoto, Y., Ishigami, M., Kuriyama, H., Kishida, K., Nishizawa, H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.8.1057 · Cited by 1,277
ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism
Berg, A. H., Combs, T. P., & Scherer, P. E. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00524-0 · Cited by 1,213
Cited by
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Farrell, G. C., & Larter, C. Z. (2006) · Hepatology · doi:10.1002/hep.20973 · Cited by 2,414
Jung, U., & Choi, M.-S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15046184 · Cited by 1,880
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Nonalcoholic fatty liver disease
Adams, L. A. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.045232 · Cited by 1,610
Adams, L. A., Anstee, Q. M., Tilg, H., & Targher, G. (2017) · Gut · doi:10.1136/gutjnl-2017-313884 · Cited by 1,174
Self-citationAdiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction
Achari, A., & Jain, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061321 · Cited by 1,158
The interaction of hepatic lipid and glucose metabolism in liver diseases
Bechmann, L. P., Hannivoort, R. A., Gerken, G., Hotamisligil, G. S., Trauner, M., & Canbay, A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.025 · Cited by 994
Insulin resistance: a metabolic pathway to chronic liver disease
Bugianesi, E., McCullough, A. J., & Marchesini, G. (2005) · Hepatology · doi:10.1002/hep.20920 · Cited by 900
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
Targher, G., Byrne, C. D., & Tilg, H. (2024) · Gut · doi:10.1136/gutjnl-2023-330595 · Cited by 897
Self-citationHepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace
Baffy, G., Brunt, E. M., & Caldwell, S. H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.027 · Cited by 858
Histopathology of Pediatric Nonalcoholic Fatty Liver Disease * #
Schwimmer, J. B., Behling, C., Newbury, R., Deutsch, R., Nievergelt, C., Schork, N. J., & Lavine, J. E. (2005) · Hepatology · doi:10.1002/hep.20842 · Cited by 747
Pathogenesis of non-alcoholic fatty liver disease
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010) · QJM · doi:10.1093/qjmed/hcp158 · Cited by 741
Adiponectin – a key adipokine in the metabolic syndrome
Whitehead, J. P., Richards, A. A., Hickman, I. J., Macdonald, G. A., & Prins, J. B. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00510.x · Cited by 644
The Role of Adiponectin in Cancer: A Review of Current Evidence
Dalamaga, M., Diakopoulos, K. N., & Mantzoros, C. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1015 · Cited by 640
Molecular pathways of nonalcoholic fatty liver disease development and progression
Bessone, F., Razori, M. V., & Roma, M. G. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2947-0 · Cited by 610
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
Mechanisms of Disease Progression in Nonalcoholic Fatty Liver Disease
Jou, J., Choi, S., & Diehl, A. (2008) · Seminars in Liver Disease · doi:10.1055/s-0028-1091981 · Cited by 482
Insulin resistance, inflammation, and non-alcoholic fatty liver disease
Tilg, H., & Moschen, A. R. (2008) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2008.08.005 · Cited by 473
Self-citationKupffer cells in non-alcoholic fatty liver disease: The emerging view
Baffy, G. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.008 · Cited by 473
Adipokines in liver diseases #
Marra, F., & Bertolani, C. (2009) · Hepatology · doi:10.1002/hep.23046 · Cited by 471
Takaki, A., Kawai, D., & Yamamoto, K. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141020704 · Cited by 447
Bugianesi, E., Pagotto, U., Manini, R., Vanni, E., Gastaldelli, A., de Iasio, R., Gentilcore, E., Natale, S., Cassader, M., Rizzetto, M., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2240 · Cited by 408
Day, C. P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.017 · Cited by 395
Nonalcoholic Fatty Liver Disease: Cytokine-Adipokine Interplay and Regulation of Insulin Resistance
Tilg, H., & Hotamisligil, G. S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.05.054 · Cited by 384
Self-citationMolecular pathways in non-alcoholic fatty liver disease
Auguet, T., Berlanga, A., Guiu-Jurado, E., & Porras, J. A. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s62831 · Cited by 379
Steatosis: Co-factor in Other Liver Diseases *
Powell, E. E., Jonsson, J. R., & Clouston, A. D. (2005) · Hepatology · doi:10.1002/hep.20750 · Cited by 374
Diagnosis and Therapy of Nonalcoholic Steatohepatitis
Torres, D. M., & Harrison, S. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.077 · Cited by 354
High Visceral and Low Abdominal Subcutaneous Fat Stores in the Obese Adolescent
Taksali, S. E., Caprio, S., Dziura, J., Dufour, S., Calí, A. M. G., Goodman, T. R., Papademetris, X., Burgert, T. S., Pierpont, B. M., Savoye, M., et al. (2008) · Diabetes · doi:10.2337/db07-0932 · Cited by 353
Stojsavljević, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i48.18070 · Cited by 325
Hepatic lipid metabolism and non-alcoholic fatty liver disease
Tessari, P., Coracina, A., Cosma, A., & Tiengo, A. (2009) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.12.015 · Cited by 314
Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis
Polyzos, S. A., Toulis, K. A., Goulis, D. G., Zavos, C., & Kountouras, J. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.003 · Cited by 311
Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease
Karmiris, K., Koutroubakis, I. E., Xidakis, C., Polychronaki, M., Voudouri, T., & Kouroumalis, E. A. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000200345.38837.46 · Cited by 305
Histological assessment of non‐alcoholic fatty liver disease
Hübscher, S. G. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02416.x · Cited by 292
Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition
Cave, M., Deaciuc, I., Mendez, C., Song, Z., Joshi-Barve, S., Barve, S., & McClain, C. (2007) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2006.12.006 · Cited by 291
Non-alcoholic fatty liver disease pathogenesis: The present and the future
Petta, S., Muratore, C., & Craxì, A. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.01.004 · Cited by 285
Non-alcoholic fatty liver disease
Smith, B. W., & Adams, L. A. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.596521 · Cited by 285
Adiponectin receptor signalling in the brain
Thundyil, J., Pavlovski, D., Sobey, C. G., & Arumugam, T. V. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01560.x · Cited by 280
The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., Zavos, C., & Tsiaousi, E. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01176.x · Cited by 277
Pathogenesis and management issues for non-alcoholic fatty liver disease
Duvnjak, M. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i34.4539 · Cited by 264
Fat as an Endocrine Organ: Relationship to the Metabolic Syndrome
Hutley, L., & Prins, J. B. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200512000-00005 · Cited by 262
Metabolic disturbances in non-alcoholic fatty liver disease
Byrne, C. D., Olufadi, R., Bruce, K. D., Cagampang, F. R., & Ahmed, M. H. (2009) · Clinical Science · doi:10.1042/cs20080253 · Cited by 258
Tilg, H., & Moschen, A. R. (2008) · Clinical Science · doi:10.1042/cs20070196 · Cited by 252
Self-citationHigh-fat diet causes iron deficiency via hepcidin-independent reduction of duodenal iron absorption
Sonnweber, T., Ress, C., Nairz, M., Theurl, I., Schroll, A., Murphy, A. T., Wroblewski, V., Witcher, D. R., Moser, P., Ebenbichler, C. F., et al. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.10.013 · Cited by 117
Self-citationCimini, F. A., Barchetta, I., Carotti, S., Bertoccini, L., Baroni, M. G., Vespasiani-Gentilucci, U., Cavallo, M.-G., & Morini, S. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i19.3407 · Cited by 101
Adiponectin: a key fat-derived molecule regulating inflammation
Tilg, H., & Wolf, A. M. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.2.245 · Cited by 71
Self-citationMeyer, M., Schwärzler, J., Jukic, A., & Tilg, H. (2024) · Biomolecules · doi:10.3390/biom14040476 · Cited by 50
Self-citationSente, T., Van Berendoncks, A. M., Fransen, E., Vrints, C. J., & Hoymans, V. Y. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00831.2015 · Cited by 41
“Thus, although adiponectin is primarily secreted by white adipose tissue, recent evidence demonstrated that adiponectin is also produced by nonadipose tissues and cell types, such as murine and human cardiomyocytes, osteoblasts, hepatocytes, C2C12 myoblasts, and skeletal muscle fibers (4, 11, 13, 21, 24, 47, 57).”
Background
Metadata
- Authors
- Kaser, S., Moschen, A., Cayon, A., Kaser, A., Crespo, J., Pons-Romero, F., Ebenbichler, C. F., Patsch, J. R., & Tilg, H.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2004-12-10
- Volume
- 54
- Issue
- 1
- Pages
- 117-121
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2145725957
- Cited by
- 412
- References
- 18
- FWCI
- 19.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.